Artelo Biosciences Inc. (ARTL), a clinical-stage pharmaceutical company, on Monday announced the publication of a peer-reviewed article in the European Journal of Pain on the potential of FABP5 as a therapeutic target for pain management, and these results encourage advancement of ART26.12, a developing analgesic.
Preclinical evidence suggests that inhibition of fatty-acid binding protein 5 (FABP5), as a novel lipid-signalling target, has an analgesic effect on visceral, inflammatory, neuropathic, and joint pain.
Artelo has evaluated ART26.12, a FABP5 inhibitor as a novel, non-opioid pain treatment for diabetic neuropathy, osteoarthritis, cancer bone pain, and peripheral neuropathy caused by chemotherapy across 7 preclinical studies.
The drug has completed a Phase 1 single ascending dose study, and the company expects to initiate a multiple ascending dose study later this year.
ARTL is currently trading at $5.16, up 16.22%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.